Vaginal Dryness Treatment Options: An Evidence Guide for Menopause

Vaginal dryness treatment becomes a common question once estrogen levels decline in perimenopause and postmenopause, and the range of options has expanded well beyond over-the-counter lubricants. This guide summarizes what current NAMS and ACOG guidance say about non-hormonal moisturizers, lubricants, low-dose vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal laser therapy. It outlines how each option works, the supporting evidence, expected timelines, safety considerations, and what costs typically look like in the United States. The aim is to help readers prepare a more informed conversation with a qualified clinician, not to replace one.

Key facts at a glance

• Vaginal dryness is the most common symptom of genitourinary syndrome of menopause (GSM), affecting roughly 27-84% of postmenopausal women¹.
• Non-hormonal moisturizers and lubricants are recommended first-line for mild symptoms, with hormonal therapy reserved for moderate-to-severe GSM¹.
• Low-dose vaginal estrogen produces serum estradiol typically under 20 pg/mL and has no required duration limit per NAMS 2020 guidance¹.
• Vaginal DHEA (prasterone) showed statistically significant improvement in dyspareunia and dryness at 12 weeks in two phase 3 trials of 813 women⁵.

What works for vaginal dryness? The direct answer

For mild vaginal dryness, the 2020 NAMS Position Statement on genitourinary syndrome of menopause recommends starting with non-hormonal moisturizers used 2-3 times per week plus a water- or silicone-based lubricant during intimacy¹. For moderate-to-severe symptoms, or when first-line measures are insufficient, low-dose vaginal estrogen, vaginal DHEA (prasterone), or oral ospemifene are evidence-supported options. Vaginal estrogen has the largest evidence base and is endorsed by both NAMS and ACOG, with serum estradiol levels at standard doses generally remaining at or below 20 pg/mL¹.

Real-world undertreatment is striking. NAMS estimates that while up to 84% of postmenopausal women report GSM symptoms, only about 7% receive prescription therapy¹. The gap reflects both under-reporting by patients and inconsistent screening in primary care. Symptoms tend to be chronic and progressive without treatment, in contrast to hot flashes, which usually improve with time. That distinction is one reason clinicians treat vaginal dryness on its own timeline rather than waiting for systemic menopause symptoms to resolve.

Why menopause causes vaginal dryness

Vaginal dryness in midlife is overwhelmingly driven by the drop in circulating estradiol that accompanies the menopause transition. The 2014 vulvovaginal atrophy terminology consensus formally renamed the condition genitourinary syndrome of menopause (GSM) to capture the full set of vulvar, vaginal, and urinary tissue changes, including dryness, burning, irritation, dyspareunia (painful intercourse), and recurrent urinary tract infections².

What changes biologically

Estrogen maintains the thickness and elasticity of the vaginal epithelium, supports glycogen production that feeds protective lactobacilli, and keeps vaginal pH acidic (typically below 4.5). When estradiol falls below roughly 20 pg/mL, the epithelium thins, glycogen drops, lactobacilli decline, and pH rises into the 5.0-7.5 range². The result is reduced lubrication, more fragile tissue, and a microbiome shift that can increase irritation and infection risk.

Symptoms beyond dryness

NAMS reports that women with GSM commonly experience three or more concurrent symptoms, including dyspareunia in 65-78% of symptomatic patients, vaginal burning or irritation in roughly 50%, and recurrent urinary symptoms in 30-50%¹. Sexual function impact is substantial. In the REJOICE trial population, baseline dyspareunia severity averaged 2.6 of 3 before treatment⁷. This clustering is part of why clinicians frame treatment around GSM rather than dryness alone.

Vaginal dryness treatment options compared

Several categories of treatment are supported by published evidence, and clinicians typically match the intensity of treatment to the severity of symptoms. The summary below is editorial and not prescriptive. Specific choices should be discussed with a clinician.

Non-hormonal moisturizers and lubricants

Vaginal moisturizers (such as hyaluronic acid or polycarbophil-based products) are designed for routine use 2-3 times weekly to maintain tissue hydration. Lubricants are used during intimacy for immediate friction reduction. NAMS recommends these as first-line for mild GSM and as adjuncts at any severity¹. A 2016 trial of polycarbophil moisturizer vs placebo showed comparable improvement in mild symptoms, while moderate-to-severe symptoms more often required additional therapy.

Low-dose vaginal estrogen

Available as creams (estradiol or conjugated estrogens), the Estring vaginal ring (7.5 mcg/day for 90 days), tablets and soft-gel inserts (Vagifem 10 mcg, Imvexxy 4-10 mcg), low-dose vaginal estrogen restores epithelial thickness and lubrication. The REJOICE trial of the 4 mcg and 10 mcg estradiol soft-gel capsule reported significant improvement in dyspareunia and vaginal dryness vs placebo at 12 weeks (p < 0.0001 for the co-primary endpoints)⁷. NAMS 2020 guidance concludes that vaginal estrogen does not require routine progestogen co-therapy or endometrial monitoring and has no required stop date when symptoms persist¹.

Vaginal DHEA (prasterone)

Prasterone (Intrarosa) is a once-daily 6.5 mg vaginal insert of dehydroepiandrosterone. In two phase 3 trials of 813 women, prasterone improved most-bothersome dyspareunia at 12 weeks vs placebo (mean improvement -1.42 vs -1.06; p = 0.0002) along with vaginal pH and dryness⁵. It is FDA-approved for moderate-to-severe dyspareunia due to menopause.

Oral ospemifene

Ospemifene (Osphena) is a selective estrogen receptor modulator (SERM) taken orally at 60 mg daily, FDA-approved for moderate-to-severe dyspareunia from GSM. Trials show improvement in dyspareunia and vaginal maturation index at 12 weeks. Because it is systemic, it carries class labeling concerns including a small thromboembolism risk.

Vaginal laser

Fractional CO2 and Er:YAG laser devices are marketed for GSM but are not FDA-approved for that use, and the FDA issued a 2018 safety communication cautioning against "vaginal rejuvenation" claims⁶. A 2021 JAMA randomized sham-controlled trial of CO2 laser found no significant difference in symptom severity at 12 months⁸. NAMS guidance considers the evidence insufficient as of 2020.

Telehealth provider options for GSM evaluation

Several US telehealth services focus specifically on menopause and offer evaluation for GSM and vaginal dryness, including prescriptions for vaginal estrogen where clinically appropriate. The brand notes below describe positioning, not rankings.

• Midi Health — virtual menopause clinic staffed by NAMS-certified clinicians; accepts many commercial insurance plans.
• Winona — cash-pay direct-to-consumer model focused on menopause-related hormone prescriptions including vaginal estrogen, with compounded options.
• Alloy — subscription menopause care with menopause-trained clinicians; ships FDA-approved hormone and non-hormonal prescriptions including vaginal estrogen.
• Gennev — telehealth menopause clinic offering MD visits and OB/GYN consultations, with several insurance and cash-pay options.

Coverage, formularies, and clinician credentialing vary by state and plan. Verify current details with each provider before booking.

Safety, contraindications, and when to see a clinician

Most non-hormonal moisturizers and lubricants are well tolerated, though some women react to glycerin, parabens, or warming agents. For low-dose vaginal estrogen, NAMS and ACOG do not require routine endometrial monitoring at standard doses, and a 2018 Women's Health Initiative Observational Study analysis of 45,663 women showed no statistically significant increase in invasive breast cancer (hazard ratio 1.04), endometrial cancer (HR 1.17), or cardiovascular events (HR 0.88)³.

Women with a history of estrogen-dependent breast cancer face a more nuanced decision. ACOG Committee Opinion 659 states that low-dose vaginal estrogen may be considered for breast cancer survivors with severe symptoms unresponsive to non-hormonal options, ideally with their oncologist's input, and notes that aromatase inhibitor users warrant particular caution⁴. Any unscheduled postmenopausal bleeding while using vaginal estrogen should be promptly evaluated by a clinician.

Symptoms that warrant clinical evaluation regardless of treatment plan include new-onset bleeding, persistent pelvic pain, lesions or ulcers, recurrent UTIs, or symptoms that do not respond to first-line measures after 8-12 weeks. Self-treatment of moderate-to-severe symptoms can delay diagnosis of other vulvar or vaginal conditions.

Cost and insurance considerations

Out-of-pocket costs vary widely by category. Non-hormonal vaginal moisturizers and lubricants commonly run $10-30 per month over the counter. Generic vaginal estradiol cream is typically $30-90 per month without insurance, while branded tablets (Vagifem, Imvexxy) and the Estring ring more often run $150-400 monthly cash-pay, though manufacturer coupons may reduce this substantially. Prasterone (Intrarosa) and ospemifene (Osphena) often exceed $200 per month without insurance.

Insurance coverage is inconsistent. Many commercial plans cover generic vaginal estradiol with prior authorization, but branded products and prasterone are often subject to step-therapy requirements. Medicare Part D coverage for vaginal estrogen has expanded since 2022 in many regions but is plan-specific. Telehealth clinics that take insurance can reduce visit costs but often do not change drug-tier pricing. Patients should verify formulary status with their own plan and pharmacy.

Frequently asked questions

What is the most effective vaginal dryness treatment for menopause?

Effectiveness depends on symptom severity. Mild dryness often responds to non-hormonal moisturizers and lubricants within 2-4 weeks. Moderate-to-severe genitourinary syndrome of menopause typically improves more substantially with low-dose vaginal estrogen, vaginal DHEA, or oral ospemifene per NAMS 2020 guidance. Treatment choice should be discussed with a clinician.

How long does it take for vaginal dryness treatment to work?

Non-hormonal moisturizers can show benefit within 2-4 weeks of consistent use. Low-dose vaginal estrogen typically improves symptoms within 2-4 weeks, with maximal benefit at 8-12 weeks per the NAMS 2020 position statement. Vaginal DHEA shows benefit at 12 weeks in pivotal trials. Lubricants act immediately during intimacy.

Can you treat vaginal dryness without hormones?

Yes. Non-hormonal vaginal moisturizers based on hyaluronic acid or polycarbophil, water- or silicone-based lubricants, pelvic floor physiotherapy, and oral ospemifene (a non-estrogen SERM) are options. NAMS recommends these as first-line for women who prefer to avoid hormones or have contraindications. Effectiveness varies by symptom severity.

Is vaginal estrogen safe for women with a history of breast cancer?

This requires individualized discussion. ACOG Committee Opinion 659 states that low-dose vaginal estrogen may be considered for breast cancer survivors with severe symptoms unresponsive to non-hormonal options, particularly those not on aromatase inhibitors. Decisions should involve the patient's oncologist and clinician.

What does vaginal dryness treatment typically cost?

Over-the-counter moisturizers and lubricants run $10-30 per month. Generic vaginal estradiol cream costs roughly $30-90 monthly without insurance, while branded tablets and rings can run $150-400. Prasterone (Intrarosa) and ospemifene (Osphena) commonly exceed $200 monthly cash-pay. Insurance coverage varies.

Can vaginal laser therapy treat dryness from menopause?

Fractional CO2 and Er:YAG vaginal laser devices are marketed for genitourinary syndrome of menopause but as of FDA 2018 safety communications and 2020 NAMS guidance, evidence remains limited and devices are not FDA-approved for this indication. Some randomized trials have not shown benefit over sham. Discuss evidence and risks with a clinician.

Sources

1. The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society. Menopause, 2020;27(9):976-992. https://pubmed.ncbi.nlm.nih.gov/32852449/
2. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology. Menopause, 2014;21(10):1063-1068. https://pubmed.ncbi.nlm.nih.gov/25160739/
3. Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause, 2018;25(1):11-20. https://pubmed.ncbi.nlm.nih.gov/28816933/
4. ACOG Committee Opinion No. 659: The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer. Obstet Gynecol, 2016;127(3):e93-e96. https://pubmed.ncbi.nlm.nih.gov/26901334/
5. Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal DHEA on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy. Menopause, 2016;23(3):243-256. https://pubmed.ncbi.nlm.nih.gov/26731686/
6. FDA Statement on efforts to safeguard women's health from deceptive health claims and significant risks related to devices marketed for "vaginal rejuvenation," July 2018. https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-efforts-safeguard-womens-health-deceptive-health-claims
7. Constantine GD, Simon JA, Pickar JH, et al. The REJOICE trial: A phase 3 randomized, controlled trial of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause, 2017;24(4):409-416. https://pubmed.ncbi.nlm.nih.gov/27922938/
8. Li FG, Maheux-Lacroix S, Deans R, et al. Effect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms: A Randomized Clinical Trial. JAMA, 2021;326(14):1381-1389. https://pubmed.ncbi.nlm.nih.gov/34636862/

Related brands & guides

Updated 2026-05-30. Reviewed by Jane Smith, MD.